The $2.7 million federal grant to the UW Medicine Departments of Genome Sciences and Pediatrics, announced on July 15, will enable BBI researchers to explore genetic basis of Mendelian conditions, including sickle cell anemia, hemophilia, and muscular dystrophy. Moreover, the work will be part of new Mendelian Genomics Research Consortium, a coalition of five clinical sites nationwide, along with a…
Dr. Stanley A. Herring, co-founder and senior medical advisor of The Sports Institute at UW Medicine, is the recipient of the 2021 Frank H. Krusen, MD, Lifetime Achievement Award by the American Academy of Physical Medicine and Rehabilitation. The award was established to honor Krusen, a founding father of the academy who pioneered the practice of physical medicine and rehabilitation. The Krusen…
Fred Hutchinson Cancer Research Center, UW Medicine, Seattle Cancer Care Alliance and Seattle Children’s today announced plans to explore restructuring their longtime relationship to accelerate a shared mission of advancing diagnosis, treatment and pioneering of cures for cancer and other diseases. If finalized and approved, the proposed restructure would establish an adult-focused oncology program and, separately, a pediatric oncology program.…
AVM Biotechnology, a clinical-stage company, announced today FDA permission to modify its ongoing clinical study, AVM0703-001, entitled “The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma”. The initial protocol, a 3 x 3-based design, called for dose escalation of 3 mg/kg for each of the six cohorts, ranging from 6 mg/kg to 21 mg/kg, with a minimum of three…
Imagine you’re in your high school math class waiting to hear back about your college applications, wondering if higher education is even within reach for you and your family. As class ends and you’re chatting with friends, you look down at your phone and see a missed call and a flurry of texts from your mom. “You got into UW!…
Kineta Inc, through its subsidiary Kineta Chronic Pain LLC, announced today that the first participant has been successfully dosed in a Phase 1 multiple ascending dose (MAD) clinical trial of KCP506, an investigational, first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the treatment of chronic neuropathic pain. The Phase 1, double blinded, placebo controlled, multiple ascending dose study…
Shigeru Kinoshita, MD, PhD, has joined the medical advisory board at Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. Professor Kinoshita is the inventor of Aurion Biotech’s lead candidate, cell therapy for the treatment of corneal endothelial disease. As a member of the company’s medical advisory board, he will…
In a report first published on the preprint server bioRxiv on June 22, Fred Hutchinson Cancer Research Center evolutionary biologist Dr. Jesse Bloom reported uncovering SARS-CoV-2 sequences from early in the Wuhan outbreak that had been deleted from a National Institutes of Health database. In a complementary Twitter thread, he explained how he had recovered raw sequencing data from 34 samples from early Wuhan SARS-CoV-2 cases, used the data in the…
The functional consequences of genetic variants within 5’ untranslated regions (UTRs) on a genome-wide scale are poorly understood in disease. Here we develop a high-throughput multi-layer functional genomics method called PLUMAGE (Pooled full-length UTR Multiplex Assay on Gene Expression) to quantify the molecular consequences of somatic 5’ UTR mutations in human prostate cancer. We show that 5’ UTR mutations can…
Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the U.S. Food and Drug Administration (FDA) granted PADCEV® (enfortumab vedotin-ejfv) regular approval in the U.S., in addition to approving a new indication for adult patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin-containing chemotherapy and have previously received…
